Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL516417 | 0.74 | ALDH1A1 (0.45) | ALDH1A1RAB9ACTSKALOX15 | |
| SCHEMBL10870183 | 0.72 | ALDH1A1 (0.44) | ALDH1A1RAB9AALOX15 | |
| SCHEMBL3965255 | 0.72 | ALDH1A1 (0.44) | ALDH1A1RAB9AALOX15 | |
| SCHEMBL8366202 | 0.68 | ALDH1A1 (0.59) | ALDH1A1RAB9ACTSKALOX15 | |
| SCHEMBL516442 | 0.67 | RAB9A (0.39) | ALDH1A1RAB9A | |
| SCHEMBL516737 | 0.67 | ALDH1A1 (0.39) | ALDH1A1RAB9A | |
| SCHEMBL516273 | 0.67 | RAB9A (0.54) | ALDH1A1RAB9A | |
| SCHEMBL517221 | 0.66 | — | — | |
| SCHEMBL7776734 | 0.66 | ALDH1A1 (0.41) | ALDH1A1RAB9A | |
| SCHEMBL516345 | 0.65 | ALDH1A1 (0.39) | ALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612075-B2 | Substituted oxoazaheterocyclyl compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-20040102450-A1 | Substituted oxoazaheterocyclyl compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2004-05-27 | — | — | US | disclosed |
| EP-1208097-A2 | SUBSTITUTED OXOAZAHETEROCYCLYL COMPOUNDS | Aventis Pharmaceuticals Inc. (US) | 2002-05-29 | — | — | EP | disclosed |
| WO-2001007436-A2 | SUBSTITUTED OXOAZAHETEROCYCLYL COMPOUNDS | AVENTIS PHARMACEUTICALS INC. (US) | 2001-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102450-A1 | Substituted oxoazaheterocyclyl compounds | F13B, F9, F11 | ALDH1A1 3776/4885RAB9A 1986/4885CTSK 371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.